Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (3): 451-458. doi: 10.19723/j.issn.1671-167X.2019.03.012

Previous Articles     Next Articles

Clinicopathological and molecular characteristics of Epstein-Barr virus associated gastric cancer: a single center large sample case investigation

Yang YANG1,Yi-qiang LIU2,Xiao-hong WANG3,Ke JI1,Zhong-wu LI2,Jian BAI4,Ai-rong YANG4,Ying HU3,Hai-bo HAN3,Zi-yu LI1,Zhao-de BU1,Xiao-jiang WU1,Lian-hai ZHANG1△(),Jia-fu JI1△()   

  1. 1. Department of Gastrointestinal Cancer Center
    2. Department of Pathology
    3. Department of Biobank, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China
    4. Berry Oncology Corporation, Beijing 102206, China
  • Received:2019-03-18 Online:2019-05-17 Published:2019-06-26
  • Supported by:
    Supported by the National Natural Science Foundation of China(81502643)

RICH HTML

 23   

PDF (PC)

440

Abstract: Objective: Epstein-Barr virus associated gastric cancer (EBVaGC) is different from the traditional gastric cancer (Epstein-Barr virus non-associated gastric cancer, EBVnGC), and has unique clinicopathological features. This study investigated the largest single center cancer series so as to establish the clinicopathological and molecular characteristics of EBVaGC in China.Methods: A retrospective analysis was conducted on EBVaGC and EBVnGC patients diagnosed at Peking University Cancer Hospital from 2003 to 2018 by comparing their clinicopathological features and prognosis. The gastric cancer (GC) dataset of public database was analyzed to obtain differentially expressed genes. The expression of important genes and their association with prognosis of GC were verified in GC tissues from our hospital. Results: In this study, 3 241 GC patients were included, and a total of 163 EBVaGC (5.0%) patients were identified. Compared with EBVnGC, EBVaGC was higher in male and younger patients, and positively associated with remnant GC, poorly differentiated adenocarcinoma, and mixed type GC. EBVaGC was inversely related to lymph node metastasis. The 5-year survival rate of EBVnGC and EBVaGC was 59.6% and 63.2% respectively (P<0.05). In order to explore molecular features of EBVaGC, the Cancer Genome Atlas (TCGA) dataset was analyzed (n=240), and 7 404 significant differentially expressed genes were obtained, involving cell proliferation, apoptosis, invasion and metastasis. The down-regulated invasion/metastasis gene SALL4 and the up-regulated immune checkpoint gene PD-L1 were important molecular features of EBVaGC. Validation of these two genes in large GC series showed that the majority of the EBVaGC was SALL4 negative (1/92, 1.1%, lower than EBVnGC, 303/1 727, 17.5%), and that PD-L1 was mostly positive in EBVaGC (81/110, 73.6%, higher than EBVnGC, 649/2 350, 27.6%). GC patients with SALL4 negative and PD-L1 positive were often associated with better prognosis.Conclusion: EBVaGC is a unique subtype of GC with less metastasis and a good prognosis. It also has a distinct molecular background. The down-regulation of invasion/metastasis gene SALL4 and up-regulation of immune checkpoint gene PD-L1 are important molecular features.

Key words: Epstein-Barr virus infections, Stomach neoplasms, Clinicopathological features, Prognosis

CLC Number: 

  • R735.2

Figure 1

EBER expression in human primary gastric cancer by in situ hybridization A, EBER negative (×200); B, EBER positive (×200); C, LELC exhibits “lace-like” pattern by HE staining (×40). EBER, Epstein-Barr virus encoded small RNA; LELC, lymphoepithelioma-like carcinoma."

Table 1

The clinicopathological features of EBVaGC"

Variables EBVaGC (n=163) EBVnGC (n=3 078) Statistics value P value
Gender, n χ2=10.783 0.001
Male 137 2 226
Female 26 852
Age/years, x?±s 55.9±10.8 59.7±11.1 t=16.959 <0.001
WHO classification, n χ2=399.138 <0.001
Adenocarcinoma 142 3 078
LELC 21 0
Lauren type, n χ2=16.547 <0.001
Intestinal-type 50 1 431
Diffuse-type 50 798
Mixed-type 63 849
Differentiation, n χ2=35.086 <0.001
Poorly 112 1 403
Moderately 51 1 581
Well 0 94
Location, n χ2=0.620 0.431
Cardia 34 814
Non-cardia 129 2 264
TNM stage, n χ2=6.797 0.079
Ⅰ 44 615
Ⅱ 32 688
Ⅲ 71 1 546
Ⅳ 16 229
T, n χ2=4.679 0.197
T1 31 499
T2 25 416
T3 62 1 437
T4 45 726
N, n χ2=4.772 0.029
Positive 92 1 996
Negative 71 1 082
M, n χ2=1.251 0.263
Positive 16 229
Negative 147 2 849
Vascular invasion, n χ2=7.775 0.005
Positive 62 1 586
Negative 91 1 460
Remnant GC or not, n χ2=8.204 0.004
Yes 7 44
No 156 3 034

Table 2

Univariate Cox regression analysis of prognostic factors for gastric cancer patients"

Variables HR (95%CI) P value
Age
18-50 1
50-90 1.156 (0.963-1.388) 0.121
Gender
Male 0.970 (0.816-1.155) 0.735
Female 1
EBER 0.040
Negative 1
Positive 0.627 (0.402-0.979)
WHO classification
Adenocarcinoma 1
LELC 0.049 (0.000-52.491) 0.398
Differentiation
Poor and moderate 1
Well 0.209 (0.078-0.558) 0.002
Location
Cardiac 1
Non-cardiac 1.065 (0.666-1.703) 0.792
TNM stage
Ⅰ 1
Ⅱ 4.402 (2.246-8.628) <0.001
Ⅲ 15.600 (8.334-29.203) <0.001
Ⅳ 18.541 (9.707-35.412) <0.001
Lymphatic metastatic
Negative 1
Positive 3.979 (3.159-5.011) <0.001

Figure 2

Kaplan-Meier curves of EBVaGC and EBVnGC A, Kaplan-Meier estimated survival after gastric cancer diagnosis by tumor Epstein-Barr virus status; B, overall survival of patients with stage Ⅰ; C, overall survival of patients with stage Ⅱ; D, overall survival of patients with stage Ⅲ; E, overall survival of patients with stage Ⅳ. Abbreviations as in Table 1."

Table 3

Multivariate Cox regression analysis of prognostic factors for gastric cancer patients"

Variables HR (95%CI) P value
EBER
Negative 1
Positive 0.609 (0.390-0.951) 0.029
TNM stage <0.001
Ⅰ 1
Ⅱ 2.904 (1.461-5.773) 0.002
Ⅲ 8.761 (4.557-16.844) <0.001
Ⅳ 10.816 (5.533-21.145) <0.001
Differentiation
Poor and moderate 1
Well 0.432 (0.161-1.163) 0.100
Lymph node metastasis
Negative 1
Positive 2.028 (1.577-2.606) <0.001

Figure 3

Differentially expressed genes and their expression levels in EBVaGC and EBVnGC from the TCGA gastric cancer dataset A, differentially expressed genes of EBVaGC (red: genes of up-regulation; green: genes of down-regulation); B, the expression of SALL4 in EBVaGC and EBVnGC; C, the expression of PD-L1 in EBVaGC and EBVnGC. TCGA, The Cancer Genome Atlas; other abbreviations as in Table 1."

Figure 4

Kaplan-Meier survival curves for SALL4 and PD-L1 differentially expressed in EBVaGC and EBVnGC A, gastric cancer patients with PD-L1 positive with good outcomes; B, gastric cancer patients with SALL4 negative with good outcomes."

[1] Horiuchi K, Mishima K, Ohsawa M , et al. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus[J]. J Clin Pathol, 1994,47(6):538-540.
doi: 10.1136/jcp.47.6.538
[2] Network CGAR . Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014,513(7517):202.
doi: 10.1038/nature13480
[3] Baek DW, Kang BW, Hwang S , et al. Clinical significance of p53 protein expression, beta-catenin expression and HER2 expression for Epstein-Barr virus-associated gastric cancer[J]. Chonnam Med J, 2017,53(2):140-146.
doi: 10.4068/cmj.2017.53.2.140
[4] Camargo MC, Kim WH, Chiaravalli AM , et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis[J]. Gut, 2014,63(2):236-243.
doi: 10.1136/gutjnl-2013-304531
[5] Camargo M, Murphy G, Koriyama C , et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis[J]. Brit J Cancer, 2011,105(1):38.
doi: 10.1038/bjc.2011.215
[6] Murphy G, Pfeiffer R, Camargo MC , et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location[J]. Gastroenterology, 2009,137(3):824-833.
doi: 10.1053/j.gastro.2009.05.001
[7] Dong M, Wang HY, Zhao XX , et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma[J]. Hum Pathol, 2016,53:25-34.
doi: 10.1016/j.humpath.2016.02.007
[8] Myers RB, Kudlow JE, Grizzle WE . Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia[J]. Mod Pathol, 1993,6(6):733-737.
[9] Yong KJ, Gao C, Lim JS , et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med, 2013,368(24):2266-2276.
doi: 10.1056/NEJMoa1300297
[10] Harn HJ, Chang JY, Wang MW , et al. Epstein-Barr virus-asso-ciated gastric adenocarcinoma in Taiwan[J]. Hum Pathol, 1995,26(3):267-271.
doi: 10.1016/0046-8177(95)90056-X
[11] Qiu K, Tomita Y, Hashimoto M , et al. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: Association with clinico-pathologic factors and HLA-subtype[J]. Int J Can-cer, 1997,71(2):155-158.
doi: 10.1002/(ISSN)1097-0215
[12] Liu S, Zhao Z, Han L , et al. Epstein-Barr virus infection in gastric remnant carcinoma and recurrent gastric carcinoma in Qingdao of Northern China[J]. PLoS One, 2016,11(2):e0148342.
doi: 10.1371/journal.pone.0148342
[13] Sukawa Y, Yamamoto H, Nosho K , et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer[J]. World J Gastroenterol, 2012,18(45):6577-6586.
doi: 10.3748/wjg.v18.i45.6577
[14] Kaizaki Y, Hosokawa O, Sakurai S , et al. Epstein-Barr virus-associated gastric carcinoma in the remnant stomach: de novo and metachronous gastric remnant carcinoma[J]. J Gastroenterol, 2005,40(6):570-577.
doi: 10.1007/s00535-005-1590-3
[15] Zhang L, Xu Z, Xu X , et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis[J]. Oncogene, 2014,33(48):5491-5500.
doi: 10.1038/onc.2013.495
[16] Kim ST, Cristescu R, Bass AJ , et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metasta-tic gastric cancer[J]. Nat Med, 2018,24(9):1449-1458.
doi: 10.1038/s41591-018-0101-z
[1] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[2] Wei-bo GAO,Mao-jing SHI,Hai-yan ZHANG,Chun-bo WU,Ji-hong ZHU. Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 921-927.
[3] Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920.
[4] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[5] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[6] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[7] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[8] CHEN Huai-an,LIU Shuo,LI Xiu-jun,WANG Zhe,ZHANG Chao,LI Feng-qi,MIAO Wen-long. Clinical value of inflammatory biomarkers in predicting prognosis of patients with ureteral urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 302-307.
[9] Shi-bo LIU,Hui GAO,Yuan-chun FENG,Jing LI,Tong ZHANG,Li WAN,Yan-ying LIU,Sheng-guang LI,Cheng-hua LUO,Xue-wu ZHANG. Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1069-1074.
[10] Ying-chao WU,Yun-long CAI,Long RONG,Ji-xin ZHANG,Jin LIU,Xin WANG. Characteristics of lymph node metastasis and evaluating the efficacy of endoscopic submucosal dissection in early gastric cancer [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1093-1097.
[11] Wei-qian CHEN,Xiao-na DAI,Ye YU,Qin WANG,Jun-yu LIANG,Yi-ni KE,Cai-hong YI,Jin LIN. Analysis of clinical features and prognosis in patients with primary Sjögren’s syndrome and autoimmune liver disease [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 886-891.
[12] Ru MA,Xin-bao LI,Feng-cai YAN,Yu-lin LIN,Yan LI. Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 240-246.
[13] Wen-peng WANG,Jie-fu WANG,Jun HU,Jun-feng WANG,Jia LIU,Da-lu KONG,Jian LI. Clinicopathological features and prognosis of colorectal stromal tumor [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 353-361.
[14] Xiao WANG,Zhao-xing LI,Huan-fang FAN,Li-ying WEI,Xu-jin GUO,Na GUO,Tong WANG. A rare case of cystadenoma in the small intestine [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 382-384.
[15] Yu-qing OUYANG,Lian-fang NI,Xin-min LIU. Prognosis factors analysis of patients with malignant solitary pulmonary nodules [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 158-162.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd